Sana Biotechnology, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Sana Biotechnology, Inc. (SANA) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$5.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-10
- Sana Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $1.12M.
- Sana Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$7.09M.
- Sana Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $5.76M.
- Sana Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.39M.
- Sana Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$4.74M.
- Sana Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$8.39M.
- Sana Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$1.52M, a 113.91% decline from fiscal 2022.
- Sana Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $10.91M, a 86.82% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$5.97M 10-Q · filed 2026-08-10 | -$215.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$7.09M 10-Q · filed 2026-05-11 | -$1.34M derived: sum of 2 quarters · filed 2026-05-11 | $54.00K derived: sum of 3 quarters · filed 2026-05-11 | -$2.94M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $7.15M derived: sum of 2 quarters · filed 2026-03-03 | $4.16M derived: sum of 3 quarters · filed 2026-08-10 | -$4.74M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.60M derived: sum of 2 quarters · filed 2026-08-10 | -$10.49M 10-Q · filed 2025-11-06 | -$13.52M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$2.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$11.88M 10-Q · filed 2026-08-10 | -$14.91M derived: sum of 3 quarters · filed 2026-08-10 | -$15.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$8.89M 10-Q · filed 2026-05-11 | -$11.92M derived: sum of 2 quarters · filed 2026-05-11 | -$12.60M derived: sum of 3 quarters · filed 2026-05-11 | -$7.46M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$3.71M derived: sum of 2 quarters · filed 2026-03-03 | $1.43M derived: sum of 3 quarters · filed 2026-03-03 | -$8.39M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$680.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.46M derived: sum of 2 quarters · filed 2025-11-06 | -$5.36M 10-Q · filed 2025-11-06 | -$5.20M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $5.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$4.68M 10-Q · filed 2025-08-11 | -$4.51M derived: sum of 3 quarters · filed 2026-03-03 | -$2.43M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$9.82M 10-Q · filed 2025-05-08 | -$9.65M derived: sum of 2 quarters · filed 2026-03-03 | -$7.57M derived: sum of 3 quarters · filed 2026-03-03 | -$1.00M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.25M derived: sum of 2 quarters · filed 2026-03-03 | $8.82M derived: sum of 3 quarters · filed 2026-03-03 | -$1.52M 10-K · filed 2026-03-03 |
| 2023-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $8.65M derived: sum of 2 quarters · filed 2024-11-08 | -$1.69M 10-Q · filed 2024-11-08 | $392.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $6.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.77M 10-Q · filed 2024-08-08 | -$1.69M derived: sum of 3 quarters · filed 2025-03-17 | $6.20M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | -$10.34M 10-Q · filed 2024-05-08 | -$8.26M derived: sum of 2 quarters · filed 2025-03-17 | -$368.00K derived: sum of 3 quarters · filed 2025-03-17 | $3.03M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $9.97M derived: sum of 2 quarters · filed 2025-03-17 | $13.37M derived: sum of 3 quarters · filed 2025-03-17 | $10.91M 10-K · filed 2025-03-17 |
| 2022-09-30 | $7.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $11.29M derived: sum of 2 quarters · filed 2023-11-08 | $8.83M 10-Q · filed 2023-11-08 | $6.78M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $3.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $939.00K 10-Q · filed 2023-08-03 | -$1.12M derived: sum of 3 quarters · filed 2024-02-29 | $2.40M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$2.46M 10-Q · filed 2023-05-08 | -$4.52M derived: sum of 2 quarters · filed 2024-02-29 | -$997.00K derived: sum of 3 quarters · filed 2024-02-29 | $6.50M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.46M derived: sum of 2 quarters · filed 2024-02-29 | $8.96M derived: sum of 3 quarters · filed 2024-02-29 | $5.84M 10-K · filed 2024-02-29 |
| 2021-09-30 | $3.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $11.02M derived: sum of 2 quarters · filed 2022-11-02 | $7.90M 10-Q · filed 2022-11-02 | $13.11M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $4.38M 10-Q · filed 2022-08-04 | $9.59M derived: sum of 3 quarters · filed 2023-03-16 | $14.13M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | -$3.12M 10-Q · filed 2022-05-10 | $2.09M derived: sum of 2 quarters · filed 2023-03-16 | $6.63M derived: sum of 3 quarters · filed 2023-03-16 | $5.38M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $5.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $9.75M derived: sum of 2 quarters · filed 2023-03-16 | $8.50M derived: sum of 3 quarters · filed 2023-03-16 | $5.52M 10-K · filed 2023-03-16 |
| 2020-09-30 | $4.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $3.29M derived: sum of 2 quarters · filed 2021-11-08 | $305.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$4.23M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | -$2.98M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $9.54M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |